Briefing.com

is little changed after reaffirming its outlook as investors wait for proof that AI investments can drive faster growth. QuickBooks and Credit Karma remain key growth engines, while slower TurboTax growth and a stagnant Mailchimp outlook raise the ex*****on bar. https://www.briefing.com/story-stocks/archive/2026/9/17/intuit-holds-outlook-steady-as-investors-await-proof-of-aidriven-growth-(intu)?utm_campaign=storystocks&utm_medium=social&utm_source=fb&utm_content=link

It wasn’t the Fed’s rate hike that surprised markets; it was the message that followed. The FOMC raised rates by 25 bp in a unanimous vote, while its projections signaled that most officials see additional tightening as appropriate this year. https://www.briefing.com/todays-free-feature?utm_campaign=freefeature&utm_medium=social&utm_source=fb&utm_content=link

is struggling with the homebuilder balancing act: keeping homes affordable without sacrificing margins. Prices fell 3%, orders declined 9%, and gross margin remained below year-ago levels as high mortgage rates and weaker buyer confidence pressured demand. https://www.briefing.com/story-stocks/archive/2026/9/17/lennar-cuts-delivery-outlook-as-weak-orders-overshadow-q3-margin-gain-(len)?utm_campaign=storystocks&utm_medium=social&utm_source=fb&utm_content=link

is higher after a sizable Q2 earnings beat, but the underlying picture remains mixed. International revenue surged 50%+, while softer transportation demand, contracting EBITDA margins, and a major Chinese antitrust penalty complicate the recovery story. https://www.briefing.com/story-stocks/archive/2026/9/16/tripcoms-eps-beat-provides-limited-boost-as-revenue-growth-slows-(tcom)?utm_campaign=storystocks&utm_medium=social&utm_source=fb&utm_content=link

is higher as talks with point to a potential U.S. expansion amid surging AI memory demand. An Ohio venture could give SK hynix its first U.S. chip fabrication capacity, but the structure, production plans, and timing remain unresolved. https://www.briefing.com/story-stocks/archive/2026/9/16/sk-hynix-and-intel-explore-ohio-chip-venture-as-ai-memory-demand-continues-to-grow-(skhy)?utm_campaign=storystocks&utm_medium=social&utm_source=fb&utm_content=link

is down 18% as its turnaround remains a work in progress. Comps improved sequentially and early Q3 trends are encouraging, but a 24% drop in adjusted EBITDA and another CEO transition are keeping investors focused on ex*****on. https://briefing.com/story-stocks/archive/2026/9/15/dave--and--busters-earnings-a-tough-quarter-but-signs-of-a-turnaround-are-in-play?utm_campaign=storystocks&utm_medium=social&utm_source=fb&utm_content=link

Bond yields and oil are driving the market. Equity futures recovered as the 10-yr yield retreated from 5.04% and WTI backed away from $104, but both remain near key thresholds. With a Fed rate hike widely expected Wednesday, rates remain the market’s biggest pressure point. https://www.briefing.com/page-one?utm_campaign=pageone&utm_medium=social&utm_source=fb&utm_content=link

Fed funds futures, the 2-yr Treasury, and inflation expectations are all pointing in the same direction: toward a September rate hike. With inflation still well above target, standing pat could create a credibility problem for the Fed. Read the latest Big Picture column: https://www.briefing.com/todays-free-feature?utm_campaign=freefeature&utm_medium=social&utm_source=fb&utm_content=link

A sharp rotation is unfolding across the AI trade. , , , and data-center infrastructure names are falling as AI safety concerns raise questions about future spending, while , , , and other cybersecurity stocks move higher. Full analysis: https://www.briefing.com/story-stocks/archive/2026/9/14/ai-under-pressure-frontier-concerns-put-chips-data-centers-in-the-hot-seat?utm_campaign=storystocks&utm_medium=social&utm_source=fb&utm_content=link

is higher as strong lung cancer data outweigh a breast cancer setback. ENHERTU cut the risk of progression or death by 37% versus standard treatment, while long-term TAGRISSO data reinforced its survival benefit. Safety and mature survival data remain key. Full analysis: https://www.briefing.com/story-stocks/archive/2026/9/14/astrazeneca-gains-as-enhertu-and-tagrisso-lung-cancer-data-offset-etcamah-setback-(azn)?utm_campaign=storystocks&utm_medium=social&utm_source=fb&utm_content=link